Paper Details

  1. Home
  2. Paper Details

Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.

Author: FleischerAlan B, KannangaraAjith P, LevitanDenise

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Evaluation StudyResearch that systematically evaluates the effectiveness of a particular program or policy. It measures its outcomes and provides important information for future decision-making.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This abstract describes the lack of published data on the efficacy of bexarotene in combination with methotrexate for the treatment of refractory cutaneous T-cell lymphoma (CTCL).
Paper Details　
Original Abstract of the Article :
Various combination therapies are used in refractory cutaneous T-cell lymphoma (CTCL). Although bexarotene has been studied in combination with psoralen photochemotherapy (PUVA), IFN-alpha and denileukin difitox, there have been no published data assessing the efficacy of the combination of bexarote...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/09546630802562427

データ提供：米国国立医学図書館（NLM）

A New Approach to Treating Cutaneous T-Cell Lymphoma

The field of [Cutaneous T-Cell Lymphoma (CTCL) Treatment] is constantly seeking more effective therapies for this challenging condition. This study investigates the efficacy of combining [Bexarotene and Methotrexate] in treating [Early-Stage Treatment-Refractory CTCL]. The researchers explored this combination therapy as a potential alternative for patients who have not responded to conventional treatments. Their findings suggest that [the combination of bexarotene and methotrexate may offer a promising therapeutic option for patients with refractory CTCL].

A New Oasis in the Desert of CTCL Treatment

This study provides a ray of hope for patients with treatment-refractory CTCL, offering a potential new avenue for managing this challenging condition. The findings highlight the importance of exploring novel combination therapies to expand treatment options and improve outcomes for patients with CTCL.

Unveiling New Pathways for CTCL Treatment

The desert of CTCL research continues to be explored, with each study unveiling new pathways towards more effective treatments. This research underscores the importance of exploring innovative combinations of therapies to address the complex nature of CTCL and improve the well-being of patients.

Dr. Camel's Conclusion

This study explores a promising new approach to treating cutaneous T-cell lymphoma, offering a potential alternative for patients who have not responded to conventional therapies. It highlights the importance of exploring innovative combination therapies to expand treatment options and improve outcomes for patients with CTCL.

Date :
  1. Date Completed 2009-08-13
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

19016373

DOI: Digital Object Identifier

10.1080/09546630802562427

Related Literature

Article Analysis
・Side Effects of bexarotene
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.